Sri Lanka’s dengue outbreak is turning into an unlikely windfall for private healthcare. Hospitals and diagnostic labs stand to collect roughly Rs2.3 billion in extra revenue this quarter as patients bypass overwhelmed public facilities for faster private care, according to investment bank CAL.
Reported dengue cases reached 82,011 through June 2026, up 150% from the 32,318 recorded in the same period last year. The surge is filling beds that would otherwise sit empty, with hospital occupancy across the sector projected to hit about 80% this quarter, up from a typical 65%. Private labs are capturing a parallel windfall as patients pay for quicker test turnaround than public facilities can provide.
The outbreak is also altering the mix of care hospitals deliver. Dengue patients need monitoring and fluids rather than surgery, and CAL estimates the surgical-to-medical patient ratio has shifted to roughly 30:70 from a normal 40:60. That dilutes revenue per patient, but CAL expects the volume of admissions to more than offset it: about 30% of reported cases are assumed to end up in private hospitals, averaging four-day stays at Rs40,000 a day, a treatment market worth about Rs2.2 billion.
Diagnostics add a smaller Rs100 million, based on an estimated testing pool three times larger than reported cases, with 45% opting for private labs at Rs1,500 a test.
CAL says Asiri Hospitals, Asiri Surgical Hospital, Durdans, Lanka Hospitals, Hemas Holdings, Nawaloka Hospitals and Singhe Hospitals as the main beneficiaries, with Durdans and Asiri best placed to capture testing demand given their 133 and 116 labs and collection centers, respectively, as of March. The firm cautions the boost is cyclical, not structural, and should fade as case counts normalize — though it comes on top of an already-tightening capacity trend, with hospital occupancy and lab utilization both climbing toward multi-quarter highs before the outbreak even began.